本页面由Tiger Trade Technology Pte. Ltd.提供服务

Recursion Pharmaceuticals, Inc.

3.25
-0.1200-3.56%
盘后3.280.0300+0.92%19:59 EDT
成交量:2,687.80万
成交额:8,804.46万
市值:17.14亿
市盈率:-2.26
高:3.42
开:3.35
低:3.21
收:3.37
52周最高:7.18
52周最低:2.98
股本:5.27亿
流通股本:4.15亿
量比:2.19
换手率:6.48%
股息:- -
股息率:- -
每股收益(TTM):-1.4410
每股收益(LYR):-1.4410
净资产收益率:-59.54%
总资产收益率:-27.72%
市净率:1.52
市盈率(LYR):-2.26

数据加载中...

2026/03/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/03/09

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/03/03

关联方拟减持公告

Form 144 | RECURSION PHARMACEUTICALS董事Borgeson Blake拟减持170000股,总价约588200美元
2026/02/25

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/02/25

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2026/02/25

重要事件披露

Form 8-K - Current report
2026/02/19

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals 董事 Christopher Gibson 拟减持40000股,总价约13.84万美元
2026/02/18

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals高管 Taylor Ben R拟减持13426股,总价约41352.08美元
2026/02/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/01/20

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals董事会成员Christopher Gibson拟减持40,000股,总价约178,800美元
2026/01/12

重要事件披露

Form 8-K - Current report
2026/01/06

关联方拟减持公告

Form 144 | RECURSION PHARMACEUTICALS董事B. Borgeson拟减持22万股,总价约95.92万美元
2026/01/05

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals董事 Gibson Christopher 拟减持4万股,总价约17万美元
2025/12/29

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals高管 Taylor Ben R拟减持21383股,总价约89万美元
2025/12/22

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals 高管 Najat Khan 拟减持124403股,总价约54.86万美元
2025/12/19

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals高管 Christopher Gibson 拟减持40000股,总价约18万美元
2025/12/08

重要事件披露

Form 8-K - Current report
2025/12/04

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals高管Christopher Gibson拟减持40000股,总市值约18.52万美元
2025/12/02

关联方拟减持公告

Form 144 | RECURSION PHARMACEUTICALS董事Blake Borgeson拟减持22万股,总价约96.14万美元